ARPA Bio
in tune with innovative solutions for early therapeutic intervention...
Analysis of CSF and blood based biomarkers using ARPA Bio's proprietary platform:
ARPA Bio's analytical platform enables the detection of low abundant CSF and plasma biomarkers at the femto-picogram / ml level. We apply our novel antibody tools in combination with the latest, state-of-the-art mass spectrometry technology, to monitor disease specific biomarkers in human biofluids. This approach allows absolute quantitation of multiple different targets of interest and therefore assess either, the early onset or progression of the disease as well as the patients adaptation to specific therapeutuc treatments.
More information about this technology will be announced soon....
